By Giulia Petroni

Evotec SE (EVT.XE) said Tuesday that it has received a $6-million payment from Bristol-Myers Squibb Co. (BMY) following the decision to include additional cell lines as part of a collaboration over neurodegenerative diseases.

The German drug discovery and development company said the partnership started in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases, and that it has been expanded with additional cell lines multiple times.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

January 07, 2020 02:30 ET (07:30 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Evotec (TG:EVT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Evotec Charts.
Evotec (TG:EVT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Evotec Charts.